FTSE MIB
33.915,15 +33,65 (+0,10%) Dow Jones
37.941,52 +166,14 (+0,44%) Nasdaq
15.446,76 -154,74 (-0,99%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,28 +0,55 (+0,66%) Bitcoin EUR
60.475,94 +538,55 (+0,90%)
Cabaletta Bio, Inc. (CABA)
| Chiusura precedente | 13,97 |
| Aperto | 13,90 |
| Denaro | 13,76 x 300 |
| Lettera | 17,70 x 200 |
| Min-Max giorno | 13,70 - 14,28 |
| Intervallo di 52 settimane | 7,69 - 26,35 |
| Volume | |
| Media Volume | 953.883 |
| Capitalizzazione | 667,664M |
| Beta (5 anni mensile) | 2,41 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,65 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 34,11 |
GlobeNewswireCabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis features parallel cohort design and the same starting dose as the CABA-201 INDs for lupus and myositis – – Three-month clinical data in initial patients treated with CABA-201 from Phase 1/2 trials in lupus and/or myositis remain on track to be reported by the first half of 2024 – PHILADELPHIA, Oct. 02, 2023 (GLO
- GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September: Jefferies Cell & Genetic Medicine Summit: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Tuesday, September 26, 20
- GlobeNewswire
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in four upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, September 6, 2023 in Boston, MA.Citi’s
